Bridget Greene is a skilled patent litigation attorney at Merchant & Gould’s Minneapolis office. She serves various industries, including biotechnology, Hatch-Waxman litigation, and general litigation. Bridget is committed to helping clients navigate the complex arena of patent litigation. Patent language requires a balance between being equivocal and precise. To help clients achieve the best possible outcome, Bridget takes her time to properly interpret this language.
During the process of supporting inventors and scientists, Bridget focuses on using the best possible language to get them the most coverage. Her analytical eye and linguistic skills help her identify potential gaps or expirations to create an effective litigation approach.
No two days are alike in the world of patent litigation. When analyzing a client’s unique legal situation and learning all the facts of a case, Bridget skillfully prioritizes pressing issues and ensures efficient timelines. By taking the time to learn about their unique situations and providing reliable communication, Bridget works to provide clients with trustworthy recommendations so they may achieve the best possible outcome.
For Section 337 investigations before the U.S. International Trade Commission (ITC), 2025 was a year of contrasts. As one example, the Federal Circuit’s long-awaited decision in Lashify, Inc. v. ITC reduced the burden for satisfying Section 337’s domestic industry requirement, under which ITC complainants must show adequate U.S. investments in practicing or exploiting the asserted intellectual property rights. But this lower threshold did not immediately result in increased Section 337 complaint filings. For much of 2025, uncertainty concerning U.S. trade policy and federal government operations likely depressed ITC complaint filings.